Navigation Links
Epigenetic therapy shows promise in hard-to-treat lung cancer
Date:11/9/2011

PHILADELPHIA -- Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential in this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

A research team at Johns Hopkins University tested a combination epigenetic therapy of azacitidine and entinostat among patients with recurrent metastatic non-small cell lung cancer who had been heavily pretreated but showed no response.

Researchers found a median survival of 6.4 months with treatment, where the typical survival for this patient population is four months.

Four of the 19 patients who received subsequent anticancer therapies had a major objective response to immediate subsequent treatment with other agents. Seven patients remain alive, including two who began treatment approximately four years ago.

This drug combination has previously shown efficacy among patients with leukemia.

"We are starting to show traction for epigenetic therapy for one of the most difficult-to-treat tumors," said Stephen A. Baylin, M.D., professor and deputy director of the Kimmel Cancer Center at Johns Hopkins University and leader of the Stand Up To Cancer (SU2C) Epigenetics Dream Team. "This study appears to show the first durable successes in solid tumors with epigenetic therapy."

The AACR will host a press conference on the findings on Wednesday, Nov. 9 at 11:00 a.m. ET.

Reporters can participate by using the following dial-in information:
U.S./Canada: (888) 647-7462
International: (201) 604-0169

The press conference will be hosted by Cancer Discovery Co-editors-in-Chief Jos Baselga, M.D., Ph.D., associate director and chief of the division of hematology/oncology at the Massachusetts General Hospital, and Lewis C. Cantley, Ph.D., director of the cancer center at the Beth Israel Deaconess Medical Center and professor of systems biology at Harvard Medical School.

The following panelists will participate:

  • Jerry Morton, 61, a firefighter from Baltimore alive more than two years after treatment with the epigenetic therapy.
  • Stephen A. Baylin, M.D., professor and deputy director of the Kimmel Cancer Center at Johns Hopkins University and leader of the SU2C Epigenetics Dream Team.
  • Charles Rudin, M.D., Ph.D., professor of oncology and associate director for clinical research at Johns Hopkins University Kimmel Cancer Center and a senior investigator on the SU2C Epigenetics Dream Team.
  • Malcolm Brock, M.D., associate professor of surgery and oncology and a leader in epigenetic correlative biomarker development at Johns Hopkins Kimmel Cancer Center.
  • Manel Esteller, M.D., Ph.D., director of the Cancer Epigenetics and Biology Program at Bellvitge Biomedical Research Institute in Barcelona.
  • Jeffrey A. Engleman, M.D., Ph.D., director of thoracic oncology at Massachusetts General Hospital.

This research is funded in part by SU2C, a Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) and the Flight Attendant Medical Research Institute.

"This research would not have been possible, especially at this accelerated pace, without SU2C," said Baylin. "Our SU2C Dream Team has benefitted enormously from the initiative's vision and visibility. The funding helps leverage other support mechanisms, like our SPORE grant from the NCI, which could never separately fund a trial of this magnitude and scope. It has enabled incredibly fruitful collaborations and allowed us, most importantly, to make a real difference in peoples' lives."


'/>"/>
Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Epigenetic pathway and new drug show promise in reversing a hard-to-treat childhood cancer
2. Researchers characterize epigenetic fingerprint of 1,628 people
3. Epigenetic study reveals new insights into breast cancer
4. Where are new schizophrenia drugs? Experts convene to explore genetic and epigenetic solutions
5. Scientists map epigenetic changes during blood cell differentiation
6. Study implicates new epigenetic player in mental retardation and facial birth defects
7. Study finds changes in fetal epigenetics throughout pregnancy
8. Epigenetic signals differ across alleles
9. Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy
10. Radiation Plus Hormone Therapy Extends Life in High-Risk Prostate Cancer
11. Gene therapy shows promise as hemophilia treatment in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and ... women in the world, and the most handsome men, look naturally attractive. Plastic ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
Breaking Medicine Technology: